tbuckley/cabot-search huggingface dataset:
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus
Authors: M. Puoti, P. Lorenzini, A. Cozzi-Lepri, A. Gori, C. Mastroianni, G. Rizzardini, G. Mazzarello, A. Antinori, A. d'Arminio Monforte, E. Girardi, A. d’Arminio Monforte, M. Andreoni, G. Angarano, A. Antinori, F. Castelli, R. Cauda, G. Di Perri, M. Galli, R. Iardino, G. Ippolito, A. Lazzarin, C.F. Perno, F. von Schloesser, P. Viale, A. Castagna, F. Ceccherini-Silberstein, A. Cozzi-Lepri, E. Girardi, S. Lo Caputo, C. Mussini, M. Puoti, M. Andreoni, A. Ammassari, C. Balotta, A. Bandera, P. Bonfanti, S. Bonora, M. Borderi, A. Calcagno, L. Calza, M.R. Capobianchi, A. Castagna, F. Ceccherini-Silberstein, A. Cingolani, P. Cinque, A. De Luca, A. Di Biagio, N. Gianotti, A. Gori, G. Guaraldi, G. Lapadula, M. Lichtner, S. Lo Caputo, G. Madeddu, F. Maggiolo, G. Marchetti, S. Marcotullio, L. Monno, C. Mussini, S. Nozza, E. Quiros Roldan, R. Rossotti, S. Rusconi, M.M. Santoro, A. Saracino, M. Zaccarelli, I. Fanti, L. Galli, P. Lorenzini, A. Rodano, M. Shanyinde, A. Tavelli, F. Carletti, S. Carrara, A. Di Caro, S. Graziano, F. Petrone, G. Prota, S. Quartu, S. Truffa, Italy A. Giacometti, A. Costantini, C. Valeriani, G. Angarano, L. Monno, C. Santoro, F. Maggiolo, C. Suardi, P. Viale, V. Donati, G. Verucchi, F. Castelli, E. Quiros Roldan, C. Minardi, T. Quirino, C. Abeli, P.E. Manconi, P. Piano, B. Cacopardo, B. Celesia, J. Vecchiet, K. Falasca, L. Sighinolfi, D. Segala, F. Mazzotta, F. Vichi, G. Cassola, C. Viscoli, A. Alessandrini, N. Bobbio, G. Mazzarello, C. Mastroianni, V. Belvisi, P. Bonfanti, I. Caramma, A. Chiodera, A.P. Castelli, M. Galli, A. Lazzarin, G. Rizzardini, A.L. Ridolfo, R. Piolini, A. Castagna, S. Salpietro, L. Carenzi, M.C. Moioli, C. Tincati, G. Marchetti, C. Mussini, C. Puzzolante, G. Lapadula, N. Abrescia, A. Chirianni, G. Borgia, F. Di Martino, L. Maddaloni, I. Gentile, R. Orlando, F. Baldelli, D. Francisci, G. Parruti, T. Ursini, G. Magnani, M.A. Ursitti, R. Cauda, M. Andreoni, V. Vullo, A. Cristaudo, A. Cingolani, G. Baldin, S. Cicalini, L. Gallo, E. Nicastri, R. Acinapura, M. Capozzi, R. Libertone, S. Savinelli, A. Latini, G. Iaiani, L. Fontanelli Sulekova, M. Cecchetto, F. Viviani, M.S. Mura, G. Madeddu, A. De Luca, B. Rossetti, P. Caramello, G. Di Perri, G.C. Orofino, S. Bonora, M. Sciandra, M. Bassetti, A. Londero, G. Pellizzer, V. Manfrin
Journal: Clinical Microbiology and Infection (2016)
Reply to Lei Kang, Lugang Huang and Jingti Zhang's Letter to the Editor re: Omar Fahmy, Mohd Ghani Khairul-Asri, Christian Schwentner, et al. Algorithm for Optimal Urethral Coverage in Hypospadias and Fistula Repair: A Systematic Review. Eur Urol 2016;70:293–8
Authors: Georgios Gakis, Omar Fahmy
Journal: European Urology (2017)
Doctors’ leader calls for government to rethink plans to replace Human Rights Act
Authors: Adrian O’Dowd
Journal: BMJ (2016)

The BMA has called on the government to rethink its plans to replace the existing Human Rights Act with a British bill of rights, saying that such a move could jeopardise people’s rights and is unnecessary.

Mark Porter, chair of the BMA, wrote to Prime Minister Theresa May asking her to reconsider the government’s position. The Human Rights Act was introduced in 1998. It allows UK nationals to rely on rights contained in the European Convention on Human Rights before the domestic …
Trastuzumab use and survival in HER2 (+) nonmetastatic breast cancer among Turkish women.
Authors: M. Kayahan, H. Kadioglu, M. Muslumanoglu, A. Igci, V. Ozmen, O. Idiz, Y. Eralp, S. Tuzlali
Journal: Journal of Clinical Oncology (2011)

56 Background: HER2 overexpression observed in 10-25% of breast cancers is associated with rapid proliferation. HER2-targeted trastuzumab has been used in metastatic breast cancer, and since 2004 in early breast cancer. However, trastuzumab therapy is expensive and long lasting resulting sometimes in cardiac side effects. In this study we tried to find out whether there was a subgroup of early breast cancer patients trastuzumab could be omitted. Methods: Records of patients treated for HER2-positive breast cancer in Istanbul Medical School between Jan 2000 and Sept 2009 were retrospectively evaluated. Disease-free survival (DFS) and overall survival (OS) were calculated either from follow-ups, or by calling. Kaplan meier and LogRank tests have been used for comparison (P&lt;0.05, 95% CI). Results: Follow up period was 32.2±14.9mo for trastuzumab group (TG, n:87) compared to 47.4±20.8mo for non-trastuzumab group (NTG, n:63) (P=0.0001). Groups were similar for age, menopausal status, size (T), histological grade and type, location, hormone responsiveness, presence of lymphovascular invasion, surgery, and use of local/systemic/hormonal therapy. NTG had more N0 cases (44.4% vs. 12.6%, P=0.0001), breast related deaths (15.9% vs. 5.7%, P=.042) and systemic metastases (27% vs. 13.8%, P=.043). Number of local recurrences was similar. Mean DFS and OS were significantly less in TG (P&lt;0.0001). However differences between DFS and OS of groups were not significant despite a considerable increase for both in TG at fifth year (P=0.147, P=0.450). No difference in DFS and OS between TG and NTG was observed when patients who had chemotherapy and/or radiotherapy and/or hormonotherapy were compared to those who did not. OS was not different between TG and NTG for T1, T2, and T3 tumors and for patients ≤35y. But in N2 and N3 tumors, use of trastuzumab increased OS significantly (P=0.007). Conclusions: Both number of events and systemic relapses were less in TG but we could not find a significant difference in DFS and OS between TG and NTG in Turkish nonmetastatic cancers. Prolonged follow up might be necessary to search for the subgroup who would not benefit, if any, as an incremental benefit in both DFS and OS was observed with trastuzumab use at fifth year.
Analysis of Fetal Hemoglobin Expression within Humanized Sickle Cell Disease Mice Overexpressing the TR2/4 Transgene.
Authors: Andrew Campbell, Osamu Tanabe, Rebekah Urbonya, Andrea Mathias, Lihong Shi, Kwaku Osei Bonsu, Rhonda Douglas, Brittne Halford, Tamika Cross, David Harrow, Donald Giacherio, James D. Engel
Journal: Blood (2010)
A Public-Private Partnership for Proactive Pharmacy-Based Outreach and Acquisition of Needed Medication in Advance of Severe Winter Weather
Authors: Nicole Lurie, Andrew Bunton, Kristina Grande, Gregg Margolis, Benjamin Howell, William H. Shrank
Journal: JAMA Internal Medicine (2016)

In the setting of a natural disaster, patients with chronic conditions may have difficulty accessing their prescribed medications, because they are left behind in an evacuation or because a refill cannot be obtained from the pharmacy in the aftermath, which happened after hurricanes Sandy and Katrina. 1,2Some natural disasters are forecasted several days in advance of their arrival, providing an opportunity for preparedness by the public and private sectors.Communication with patients about upcoming storms and the need to refill medications may ensure medication access and prevent exacerbations of chronic diseases.In a collaboration between the US Department of Health and Human Services and CVS pharmacies, we assessed whether consumer-centric outreach to encourage medication acquisition would increase access to prescribed medications.Methods | On January 20, 2016, the Department of Health and Human Services identified Jonas, a blizzard projected to affect the Mid-Atlantic United States, as having the potential to restrict the public's ability to get to their pharmacies.On January 21 and 22, before the storm, CVS pharmacies contacted 2.1 million patients who were taking long-term medications, had filled a medication in the past 90 days, and were customers at more than 600 stores in Maryland, Virginia, West Virginia, Kentucky, and Washington, DC, urging them to check their medication supply.Of those customers, 1.28 million contacts were via automated telephone calls and
Single-Agent Dasatinib Does Not Prevent Hematological Relapse in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Complete Remission, but Persistent or Re-Appearing Molecular Minimal Residual Disease–Results of the DASA-CBF Trial From the French AML Intergroup
Authors: Nicolas Boissel, Eric Jourdan, Arnaud Pigneux, Odile Blanchet, Aline Renneville, Christian Recher, Emmanuel Raffoux, Pascale Cornillet-Lefebvre, Jean-Michel Cayuela, Jacques Delaunay, Eric Delabesse, Claude-Eric Bulabois, Céline Berthon, Cécile Pautas, Norbert Vey, Bruno Lioure, Xavier Thomas, Leila Kammoun, Edouard Randriamalala, Nathalie Fegueux, Thibaud Lecerf, Marie-Christine Béné, Claude Preudhomme, Hesham Mohamed, Hervé Dombret, Norbert Ifrah
Journal: Blood (2011)
Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis
Authors: Parambir S Dulai, Siddharth Singh, Evelyn Marquez, Rohan Khera, Larry J Prokop, Paul J Limburg, Samir Gupta, Mohammad Hassan Murad
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To assess the comparative efficacy and safety of candidate agents (low and high dose aspirin, non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs), calcium, vitamin D, folic acid, alone or in combination) for prevention of advanced metachronous neoplasia (that is, occurring at different times after resection of initial neoplasia) in individuals with previous colorectal neoplasia, through a systematic review and network meta-analysis. <b>Data sources</b>&nbsp;Medline, Embase, Web of Science, from inception to 15 October 2015; clinical trial registries. <b>Study selection</b>&nbsp;Randomized controlled trials in adults with previous colorectal neoplasia, treated with candidate chemoprevention agents, and compared with placebo or another candidate agent. Primary efficacy outcome was risk of advanced metachronous neoplasia; safety outcome was serious adverse events. <b>Data extraction</b>&nbsp;Two investigators identified studies and abstracted data. A Bayesian network meta-analysis was performed and relative ranking of agents was assessed with surface under the cumulative ranking (SUCRA) probabilities (ranging from 1, indicating that the treatment has a high likelihood to be best, to 0, indicating the treatment has a high likelihood to be worst). Quality of evidence was appraised with GRADE criteria. <b>Results</b>&nbsp;15 randomized controlled trials (12 234 patients) comparing 10 different strategies were included. Compared with placebo, non-aspirin NSAIDs were ranked best for preventing advanced metachronous neoplasia (odds ratio 0.37, 95% credible interval 0.24 to 0.53; SUCRA=0.98; high quality evidence), followed by low-dose aspirin (0.71, 0.41 to 1.23; SUCRA=0.67; low quality evidence). Low dose aspirin, however, was ranked the safest among chemoprevention agents (0.78, 0.43 to 1.38; SUCRA=0.84), whereas non-aspirin NSAIDs (1.23, 0.95 to 1.64; SUCRA=0.26) were ranked low for safety. High dose aspirin was comparable with low dose aspirin in efficacy (1.12, 0.59 to 2.10; SUCRA=0.58) but had an inferior safety profile (SUCRA=0.51). Efficacy of agents for reducing metachronous colorectal cancer could not be estimated. <b>Conclusions</b>&nbsp;Among individuals with previous colorectal neoplasia, non-aspirin NSAIDs are the most effective agents for the prevention of advanced metachronous neoplasia, whereas low dose aspirin has the most favorable risk:benefit profile. <b>Registration</b>&nbsp;PROSPERO (CRD42015029598).
Androgen-regulated metabolome in prostate cancer.
Authors: N. Putluri, Y. Zhang, V. Putluri, S. Vareed, V. T. Vasu, S. M. Fischer, C. Chad, A. Sreekumar
Journal: Journal of Clinical Oncology (2011)

25 Background: Prostate cancer (PC) is the second most prevalent cancer among American men which is primarily treated by androgen ablation therapy. Although a number of patients respond to this regimen, a significant subset fail and the tumor invariably progresses into a hormone refractory metastatic state, which is lethal. Earlier we had reported the first unbiased metabolomic signature for localized and metastatic prostate cancer tissues. Advancing further, we attempt to delineate the subset of metabolome in prostate cancer which is regulated by androgen-action. Methods: Androgen responsive (R22V1, LnCap and VCAP) and independent (PC3, DU145) PC cells and benign prostate epithelial cells (RWPE) were profiled for their metabolomic alterations using mass spectrometry. Extracted metabolome from these cells were profiles using a combination quadrupole-time-of-flight (Q-TOF) and triple quadrupole (QQQ) mass spectrometers coupled to reverse phase and aqueous normal phase chromatography. The metabolomic profiles were analyzed to delineate class-specific signatures which were interrogated for altered bioprocesses using Oncomine Concept Map (OCM, www.oncomine.org ). The androgen receptor (AR) regulated metabolome was verified using treatment of PC cells with synthetic androgen, R1881. Results: A total of 3,092 metabolites (113 named) were detected across the 4 cells lines, of which 869 compounds were significantly (ANOVA P&lt;0.01) different between androgen responsive and non-responsive cells. The differential compendia included 28 named metabolites, including sarcosine which was earlier shown to be elevated during PC development and progression. Bioprocess mapping of AR-regulated metabolome revealed enrichment of amino acid metabolism and methylation potential, both of which were earlier defined to be the hallmarks of PC development and progression. Conclusions: The study defines AR-regulated metabolic signature which portrays enrichment of amino acid metabolism and methylation potential that are hallmarks of PC development and progression. No significant financial relationships to disclose.
Significance of mortalin expression in gastric cancer with normal p53.
Authors: Koji Ando, Eiji Oki, Zhao Yan, Hiroyuki Kitao, Hiroshi Saeki, Takefumi Ohga, Yoshihiro Kakeji, Shunichi Tsujitani, Shunji Kohnoe, Yoshihiko Maehara
Journal: Journal of Clinical Oncology (2012)

25 Background: Gastric cancer still has the highest morbidity rate and the second highest mortality rate. As chemotherapy confers only a minimal survival advantage, the prognosis of patients with advanced or recurrent gastric cancer remains poor. Studying the mechanisms and underlying molecules that drives gastric cancer malignant, could contribute to finding a remedy for gastric cancer. Mortalin is a heat non-inducible member of the heat shock protein 70 family. Mortalin binds to p53 and prevents p53 from entering the nucleus, as well as cell stress. To understand the significance of mortalin in gastric cancer, we investigated the expression of mortalin and p53. Methods: The expression of mortalin and p53 were examined by immunohistochemical staining of 182 clinical samples of gastric cancer. Results: Mortalin-positive and aberrant-p53-positive samples were found in 75.2% and 62.6% of cases, respectively. Mortalin-positive tumors were deeper in invasion and had more lymph node and liver metastases compared with mortalin-negative tumors (p &lt; 0.01, p &lt; 0.05, respectively). Mortalin-positive tumors had worse prognosis compared with mortalin-negative tumors (p = 0.035). Moreover, in tumors with normal p53 expression, mortalin-positive tumors had especially worse prognosis compared with mortalin-negative tumors (p = 0.013). With multivariate analysis, mortalin expression appeared to be an independent prognostic factor in gastric cancer with expression of normal p53 (p = 0.0174). Conclusions: Mortalin has a great impact on gastric cancer with normal p53. Therefore, mortalin is a target molecule for treatment of gastric cancer, as well as a promising prognostic factor, especially in tumors with normal p53.
Culprit or Bystander? The Role of the Fallopian Tube in “Ovarian” High-Grade Serous Carcinoma
Authors: Elizabeth M. Swisher, Rochelle L. Garcia, Mark R. Kilgore, Barbara M. Norquist
Journal: Cancer Discovery (2016)

Abstract Summary: The concurrence of intraepithelial high-grade neoplasia in the fallopian tube with metastatic implants has been taken as evidence of a tubal origin for high-grade serous pelvic carcinomas. In the current issue, Eckert and colleagues perform detailed genomic phylogenetic analyses and demonstrate that some cases of high-grade serous intraepithelial tubal neoplasia are metastatic implants and not precursor lesions. Cancer Discov; 6(12); 1309–11. ©2016 AACR. See related article by Eckert and colleagues, p. 1342.
Quantitative Measurement of VWF Binding to the Platelet Integrin αIIbβ3 - Abnormalities Identified in Individuals with VWD
Authors: Robert R. Montgomery, Veronica H Flood, Jieqing Zhu, Pamela A Christopherson, Peter J. Newman, Daniel W. Bougie, Patti Morateck
Journal: Blood (2015)
Mir-130a-Mediated Downregulation of SMAD4 Contributes to Reduced Sensitivity to TGFβ Stimulation in Promyelocytic Cells,
Authors: Mattias Hager, Corinna Cavan Pedersen, Maria Torp Larsen, Mette Klarskov Andersen, Christoffer Hother, Kirsten Grønbæk, Hanne Jarmer, Niels Borregaard, Jack B Cowland
Journal: Blood (2011)
A Novel Triple Purge Strategy for Eliminating Chronic Myelogenous Leukemia (CML) Cells from Autografts.
Authors: H. Yang, C. Eaves, M. de Lima, M. Lee, R. Champlin, J. McMannis, S. Robinson, T. Niu, W. Decker, D. Xing, M. Thomas, J. Ng, S. Li, A. Eaves, R. Jones, B. Andersson, E. Shpall
Journal: Blood (2004)
Use of radiographic progression to predict overall survival in men with castration-refractory prostate cancer.
Authors: Kazumi Kamoi, Koji Okihara, Natsuki Takaha, Tsuyoshi Iwata, Akihiro Kawauchi, Tsuneharu Miki
Journal: Journal of Clinical Oncology (2012)

254 Background: The purpose of this study was to analyze prognostic factors to predict overall survival in patients with castration-refractory prostate cancer (CRPC). Methods: A total of 68 patients with CRPC treated by secondary hormonal therapy (dexamethasone) and/or chemotherapy including docetaxel were analyzed. Primary endpoint was survival after PSA relapse. PSA relapse was defined as 3 consecutive PSA increase and serum PSA more than 4 ng/ml. Factors analyzed to predict survival were initial PSA value, initial clinical stage, pathological tumor grade (WHO grade), time to PSA relapse, nadir PSA value, time to nadir PSA, age at PSA relapse, PSA value at relapse, radiographic progression revealed by bone scan or CT scan, and bone pain. Univariate and multivariate analysis were performed using Cox regression hazard model. Results: Univariate analysis revealed nadir PSA value, time to nadir PSA, PSA value at relapse, radiographic progression revealed by bone scan or CT scan, and bone pain were significant predictors (p&lt;0.05). Multivariate analysis revealed only radiographic progression was the independent predictor for survival after PSA relapse (p=0.039). Median survival time was 63.5 and 23.5 months in patients with (n=39) and without (n=29) radiographic progression, respectively (log-rank p=0.0002). Median survival time in 39 patients with radiographic progression in bone (n=31), lymph nodes (n=6), visceral lesion (n=3), and local lesion (n=4) were 23.5, 5, 2, and 12.5 months, respectively. Conclusions: For patients with PSA relapse after hormonal therapy, the finding of radiographic progression was the only independent factor to predict overall survival.
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT
Authors: Florent Malard, Myriam Labopin, Gernot Stuhler, Johanna Tischer, Joerg Thomas Bittenbring, Arnold Ganser, Nicolaus Kroeger, Donald Bunjes, Christoph Schmid, Jiri Mayer, Mauricette Michallet, Michael Hallek, Bipin N. Savani, Mohamad Mohty, Arnon Nagler
Journal: Blood (2015)
Complications and mortality of percutaneous balloon mitral commissurotomy. A report from the National Heart, Lung, and Blood Institute Balloon Valvuloplasty Registry.
Journal: Circulation (1992)

BACKGROUND In response to the increasing use of percutaneous balloon mitral commissurotomy, the National Heart, Lung, and Blood Institute established the Balloon Valvuloplasty Registry in November 1987. METHODS AND RESULTS Between November 1, 1987, and October 31, 1989, 738 patients aged 18 or older underwent percutaneous balloon mitral commissurotomy at the clinical sites. Data were prospectively entered into the registry at the time consent was obtained. Serious complications occurred in 87 procedures, or 12%. Death in the laboratory occurred in eight patients, or 1%. Within 30 days there were 24 cumulative deaths, 18 cardiac and six noncardiac. Univariate analysis revealed that older age, a history of cardiac arrest, cerebrovascular disease, dementia, renal insufficiency, cachexia, class IV congestive heart failure, use of an intra-aortic balloon pump, use of sympathomimetic amines, and a high echo score (greater than or equal to 13) were associated with early death (p less than 0.01). Additional univariate predictors included a precommissurotomy mitral valve area of less than 0.7 cm2. Left atrial pressure greater than 12 mm Hg and a mitral valve area of less than 1.5 cm2 after the procedure were also associated with higher 30-day mortality (p less than 0.05). Multivariate analysis identified higher echo score and smaller valve area before the procedure as the strongest predictors of early death (p less than 0.001). Centers that performed more than 25 procedures also had lower complication rates. CONCLUSIONS Although percutaneous balloon mitral commissurotomy appears to be effective at relieving the hemodynamic effects of rheumatic mitral stenosis, it does have risks. In properly selected patients, however, it appears to have low morbidity and 30-day mortality. Individual center experience with the procedure also appears to have great impact on complications.
Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study.
Authors: Jennifer R. Brown, Wendy Stock, Harvey I. Katzen, Agustin J. Suarez, Shailendra Lakhanpal, Jose F. Leis, Christopher Flowers
Journal: Blood (2006)
Phase II Trial of Abbreviated CHOP-Rituximab Followed by 90Y Ibritumomab Tiuxetan (Zevalin) and Rituximab in Patients with Previously-Untreated Follicular Non-Hodgkin Lymphoma (NHL).
Authors: Nicholas A. DeMonaco, Michael Wu, Jennifer Osborn, Terry Evans, Kenneth A. Foon, Steven H. Swerdlow, Jeffrey Kant, Judith Joyce, Stephanie R. Land, Samuel A. Jacobs
Journal: Blood (2005)